Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
A team of experts at Fortis Gurugram conducted 3-dimensional mapping with the help of the new system Carto version 7 to precisely map the source of the arrhythmia. It was detected that the arrhythmia was coming from the conduction system i.e. body’s natural wiring.
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The medicine was well tolerated, with no unexpected safety issue
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated
